Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Allarity Therapeutics, Inc. stock logo
ALLR
Allarity Therapeutics
$1.66
-10.8%
$1.20
$0.61
$3.91
$27.19M0.1621.45 million shs830,686 shs
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
$3.50
-2.5%
$3.64
$2.57
$6.77
$22.18M0.575,901 shs2,276 shs
Palisade Bio, Inc. stock logo
PALI
Palisade Bio
$0.60
+2.7%
$0.80
$0.53
$4.32
$5.31M1.4533,810 shs192,968 shs
Synergy CHC Corp. stock logo
SNYR
Synergy CHC
$2.16
-1.4%
$3.13
$1.30
$10.00
$20.68MN/A106,527 shs79,261 shs
Analysts Agree—These Gold Picks Outshine the Rest Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Allarity Therapeutics, Inc. stock logo
ALLR
Allarity Therapeutics
-10.75%-15.74%+66.02%+106.65%-56.20%
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
-2.51%-2.78%-7.16%+1.19%-45.14%
Palisade Bio, Inc. stock logo
PALI
Palisade Bio
+2.75%-4.55%-26.25%-6.58%-83.57%
Synergy CHC Corp. stock logo
SNYR
Synergy CHC
-1.37%-6.90%-44.04%+3.85%+980.00%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Allarity Therapeutics, Inc. stock logo
ALLR
Allarity Therapeutics
$1.66
-10.8%
$1.20
$0.61
$3.91
$27.19M0.1621.45 million shs830,686 shs
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
$3.50
-2.5%
$3.64
$2.57
$6.77
$22.18M0.575,901 shs2,276 shs
Palisade Bio, Inc. stock logo
PALI
Palisade Bio
$0.60
+2.7%
$0.80
$0.53
$4.32
$5.31M1.4533,810 shs192,968 shs
Synergy CHC Corp. stock logo
SNYR
Synergy CHC
$2.16
-1.4%
$3.13
$1.30
$10.00
$20.68MN/A106,527 shs79,261 shs
Analysts Agree—These Gold Picks Outshine the Rest Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Allarity Therapeutics, Inc. stock logo
ALLR
Allarity Therapeutics
-10.75%-15.74%+66.02%+106.65%-56.20%
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
-2.51%-2.78%-7.16%+1.19%-45.14%
Palisade Bio, Inc. stock logo
PALI
Palisade Bio
+2.75%-4.55%-26.25%-6.58%-83.57%
Synergy CHC Corp. stock logo
SNYR
Synergy CHC
-1.37%-6.90%-44.04%+3.85%+980.00%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Allarity Therapeutics, Inc. stock logo
ALLR
Allarity Therapeutics
3.00
Buy$9.00442.17% Upside
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
0.00
N/AN/AN/A
Palisade Bio, Inc. stock logo
PALI
Palisade Bio
3.00
Buy$12.001,906.69% Upside
Synergy CHC Corp. stock logo
SNYR
Synergy CHC
3.50
Strong Buy$10.00362.96% Upside

Current Analyst Ratings Breakdown

Latest PALI, ALLR, NAII, and SNYR Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/28/2025
Allarity Therapeutics, Inc. stock logo
ALLR
Allarity Therapeutics
Ascendiant Capital Markets
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$9.00
(Data available from 9/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Allarity Therapeutics, Inc. stock logo
ALLR
Allarity Therapeutics
N/AN/AN/AN/A$1.62 per shareN/A
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
$113.80M0.19N/AN/A$13.32 per share0.26
Palisade Bio, Inc. stock logo
PALI
Palisade Bio
$250K21.82N/AN/A$2.71 per share0.22
Synergy CHC Corp. stock logo
SNYR
Synergy CHC
$34.83M0.59$0.26 per share8.23($1.91) per share-1.13
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Allarity Therapeutics, Inc. stock logo
ALLR
Allarity Therapeutics
-$24.51MN/A0.00N/AN/AN/A-173.31%-102.57%11/13/2025 (Estimated)
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
-$7.22M-$1.39N/AN/A-6.56%-10.34%-5.19%9/26/2025 (Estimated)
Palisade Bio, Inc. stock logo
PALI
Palisade Bio
-$14.44M-$4.06N/AN/AN/AN/A-214.94%-135.09%11/11/2025 (Estimated)
Synergy CHC Corp. stock logo
SNYR
Synergy CHC
$2.12M$0.385.683.66N/A10.02%-18.56%20.28%N/A

Latest PALI, ALLR, NAII, and SNYR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/15/2025Q2 2025
Allarity Therapeutics, Inc. stock logo
ALLR
Allarity Therapeutics
-$0.21-$0.15+$0.06-$0.15N/AN/A
8/14/2025Q2 2025
Synergy CHC Corp. stock logo
SNYR
Synergy CHC
$0.08$0.17+$0.09$0.17$10.80 million$6.74 million
8/11/2025Q2 2025
Palisade Bio, Inc. stock logo
PALI
Palisade Bio
-$0.48-$0.58-$0.10-$0.58N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Allarity Therapeutics, Inc. stock logo
ALLR
Allarity Therapeutics
N/AN/AN/AN/AN/A
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
N/AN/AN/AN/AN/A
Palisade Bio, Inc. stock logo
PALI
Palisade Bio
N/AN/AN/AN/AN/A
Synergy CHC Corp. stock logo
SNYR
Synergy CHC
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Allarity Therapeutics, Inc. stock logo
ALLR
Allarity Therapeutics
N/A
2.31
2.31
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
0.11
2.51
1.35
Palisade Bio, Inc. stock logo
PALI
Palisade Bio
N/A
1.62
1.62
Synergy CHC Corp. stock logo
SNYR
Synergy CHC
N/A
2.74
2.41

Institutional Ownership

CompanyInstitutional Ownership
Allarity Therapeutics, Inc. stock logo
ALLR
Allarity Therapeutics
11.53%
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
32.40%
Palisade Bio, Inc. stock logo
PALI
Palisade Bio
11.79%
Synergy CHC Corp. stock logo
SNYR
Synergy CHC
N/A

Insider Ownership

CompanyInsider Ownership
Allarity Therapeutics, Inc. stock logo
ALLR
Allarity Therapeutics
0.08%
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
20.90%
Palisade Bio, Inc. stock logo
PALI
Palisade Bio
0.65%
Synergy CHC Corp. stock logo
SNYR
Synergy CHC
56.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
Allarity Therapeutics, Inc. stock logo
ALLR
Allarity Therapeutics
1014.62 million14.61 millionNot Optionable
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
2906.18 million4.89 millionNot Optionable
Palisade Bio, Inc. stock logo
PALI
Palisade Bio
109.12 million9.06 millionNot Optionable
Synergy CHC Corp. stock logo
SNYR
Synergy CHC
409.44 million4.10 millionN/A

Recent News About These Companies

Critical Survey: Synergy CHC (SNYR) and Its Competitors
Head-To-Head Analysis: Synergy CHC (SNYR) vs. Its Rivals
Analyzing Synergy CHC (SNYR) and Its Competitors
Synergy CHC (SNYR) vs. The Competition Head to Head Analysis
Synergy CHC (SNYR) vs. The Competition Financial Survey
Synergy CHC Completes $4.375M Public Offering
Synergy CHC's (NASDAQ:SNYR) Earnings Quality Is Low
Synergy Chc EPS Jumps 86 Percent in Q2

New MarketBeat Followers Over Time

Media Sentiment Over Time

Allarity Therapeutics stock logo

Allarity Therapeutics NASDAQ:ALLR

$1.66 -0.20 (-10.75%)
Closing price 09/12/2025 04:00 PM Eastern
Extended Trading
$1.66 0.00 (0.00%)
As of 09/12/2025 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA (ixabepilone), a selective microtubule inhibitor in phase 2 for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. Allarity Therapeutics, Inc. has a collaboration with Detsamma Investments Pty. Ltd. to develop Deflexifol for the treatment of solid tumors. The company was incorporated in 2004 and is headquartered in Boston, Massachusetts.

Natural Alternatives International stock logo

Natural Alternatives International NASDAQ:NAII

$3.55 -0.04 (-1.11%)
As of 09/12/2025 04:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Natural Alternatives International, Inc. engages in formulating, manufacturing, and marketing nutritional supplements in the United States, Europe, Australia, Asia, Mexico, and Canada. The company operates in two segments, Private-Label Contract Manufacturing, and Patent and Trademark Licensing. It offers private-label contract manufacturing services to companies that market and distribute vitamins, minerals, herbal, and other nutritional supplements, as well as other health care products. The company also provides strategic partnering services, such as customized product formulation, clinical study design and support, manufacturing, marketing support, international regulatory and label law compliance, international product registration, packaging in multiple formats and labeling design, scientific research, proprietary ingredients, customer-specific nutritional product formulation, product testing and evaluation, marketing management, packaging and delivery system design, regulatory review, and international product registration assistance. In addition, it sells beta-alanine ingredient under the CarnoSyn and SR CarnoSyn names. The company manufactures products in various forms, including capsules, tablets, chewable wafers, and powders. Its private-label contract manufacturing customers include companies that market nutritional supplements through direct sales marketing channels, direct to consumer e-commerce channels, and retail stores. The company was founded in 1980 and is headquartered in Carlsbad, California.

Palisade Bio stock logo

Palisade Bio NASDAQ:PALI

$0.60 +0.02 (+2.75%)
Closing price 09/12/2025 04:00 PM Eastern
Extended Trading
$0.60 +0.00 (+0.17%)
As of 09/12/2025 07:18 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor, currently under pre-clinical development as a therapeutic for patients living with inflammatory bowel diseases, including ulcerative colitis and Crohn's disease (CD), as well as develops PALI-1908, an oral, selective PDE4 inhibitor prodrug that is locally bioactivated in the terminal ileum of CD patients, currently in the research stage. It has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; a license agreement with the Regents of the University of California; a co-development and distribution agreement with Newsoara Biopharma Co., Ltd; and a transformative strategic collaboration with Strand Life Sciences for advancing precision medicine for ulcerative colitis therapy. The company is based in Carlsbad, California.

Synergy CHC stock logo

Synergy CHC NASDAQ:SNYR

$2.16 -0.03 (-1.37%)
As of 09/12/2025 04:00 PM Eastern

Synergy CHC Corp. engages in the marketing and distribution of branded health and wellness products. The company was founded on December 29, 2010 and is headquartered in Westbrook, ME.